Andres Y. Maldonado, an analyst from H.C. Wainwright, reiterated the Buy rating on enGene Holdings. The associated price target remains the same with $25.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight enGene Holdings’ strategic positioning in the NMIBC market. The company’s product, detalimogene, is noted for its non-viral genetic medicine design, which offers clinical activity, tolerability, and ease of use, making it attractive for broad community urology adoption. This is particularly important as it remains competitive against JNJ’s Inlexzo, which, despite its recent approval, presents safety concerns and operational complexities that detalimogene avoids.
Additionally, enGene’s pivotal LEGEND trial and the FDA’s RMAT designation are key elements in its favor. The RMAT designation, in particular, allows for increased regulatory interaction and potentially faster approval timelines, enhancing detalimogene’s market prospects. The simplicity and operational efficiency of detalimogene are expected to drive its adoption in community practices, where ease of use is prioritized. These factors collectively support Maldonado’s optimistic outlook and the reiterated Buy rating with a $25 price target.
According to TipRanks, Y. Maldonado is a 4-star analyst with an average return of 8.6% and a 49.64% success rate. Y. Maldonado covers the Healthcare sector, focusing on stocks such as I-MAB, ImmunityBio, and Merus.
In another report released on September 10, Raymond James also maintained a Buy rating on the stock with a $23.00 price target.